|
1
|
Fricke J, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, Geistlich S, Borgna F, Fani M, Bernhardt P, van der Meulen NP, Müller C, Schibli R, Wild D. First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([ 161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum. Eur J Nucl Med Mol Imaging 2024:10.1007/s00259-024-06641-w. [PMID: 38448550 DOI: 10.1007/s00259-024-06641-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Accepted: 01/31/2024] [Indexed: 03/08/2024]
Affiliation(s)
- Julia Fricke
- Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
| | - Frida Westerbergh
- Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
| | - Lisa McDougall
- Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
| | - Chiara Favaretto
- Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland
| | - Emanuel Christ
- ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland
- Division of Endocrinology, University Hospital Basel, Basel, Switzerland
| | - Guillaume P Nicolas
- Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
- ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland
| | - Susanne Geistlich
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland
| | - Francesca Borgna
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland
| | - Melpomeni Fani
- Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland
| | - Peter Bernhardt
- Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
- Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Nicholas P van der Meulen
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland
- Laboratory of Radiochemistry, Paul Scherrer Institute (PSI), Villigen, Switzerland
| | - Cristina Müller
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - Roger Schibli
- Center for Radiopharmaceutical Sciences, Paul Scherrer Institute (PSI), Villigen, Switzerland
- Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
| | - Damian Wild
- Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland.
- ENETS Center of Excellence for Neuroendocrine and Endocrine Tumours, University Hospital Basel, Basel, Switzerland.
| |
Collapse
|